Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BlossomHill TherapeuticsBLSM -0.06%8 Equity-to-Asset is -0.81 as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100. Among 1,411 Biotechnology companies, BlossomHill Therapeutics ranks worse than 70871.65% on this metric.
The historical rank and industry rank for BlossomHill Therapeutics's Equity-to-Asset or its related term are showing as below:
BLSM's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BlossomHill Therapeutics Equity-to-Asset Related Terms
BlossomHill Therapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics Equity-to-Asset Chart
BlossomHill Therapeutics Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
-0.68
-0.81
BlossomHill Therapeutics Semi-Annual Data
Dec24
Dec25
Equity-to-Asset
-0.68
-0.81
BLSM vs : Equity-to-Asset Comparison
For the Biotechnology subindustry, BlossomHill Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BlossomHill Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BlossomHill Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BlossomHill Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics (BLSM) has a Equity-to-Asset of -0.81 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BlossomHill Therapeutics and its competitors. According to the industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1411 companies in the Biotechnology industry.
Is BlossomHill Therapeutics' Equity-to-Asset too high?
BlossomHill Therapeutics' current Equity-to-Asset is -0.81. Based on the distribution chart, BlossomHill Therapeutics ranks #999999 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Equity-to-Asset compare to ?
According to the Biotechnology industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1411 companies for Equity-to-Asset. This places BlossomHill Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BlossomHill Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BlossomHill Therapeutics's current Equity-to-Asset is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Equity-to-Asset of -0.81. The current Equity-to-Asset is -0.81. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Equity-to-Asset is -0.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score
Get the complete analysis for BLSM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSM has been successfully added to your 
